• Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addiction
• Mydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment options
• The license allows Mydecine to provide psilocybin and MDMA (Ecstasy) through its licensed Alberta facility and collaboration with non-profit drug development institute Applied Pharmaceutical Innovation
• The company has named pharmaceutical scientist and entrepreneur Dr. Victoria Hale to its Board of Directors, strengthening the board’s well of experience
• Hale is the board chairwoman for the non-profit Multidisciplinary Association for Psychedelic Studies, which helps scientists design, fund, and obtain regulatory approval for their psychedelics studies

British Columbia, Canada-headquartered Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) is a research-based company working to develop and commercialize psychedelic drugs that may prove effective in treating mental illnesses as government regulators become increasingly open to psychedelics’ potential. A pair of recent announcements show a more immediate response to providing mental health solutions and strengthening the company’s leadership role. The dealer license which Mydecine operates under is listed as an eligible supplier in Canada enabling the company to provide drug products for Health Canada’s Special Access Program (“SAP”). SAP allows healthcare providers to seek specific drugs normally unavailable for sale in Canada for patients with serious or life-threatening conditions who are not responding to conventional, approved treatment options or whose anticipated treatments are simply not marketed in Canada, according to a Feb. 8 announcement (https://ibn.fm/NF5mV). Mydecine’s exclusive agreement with not-for-profit drug development institute Applied Pharmaceutical Innovation (“API”) provides it a licensed dealer facility in Edmonton, Alberta, that can manufacture psilocybin and MDMA (3,4-methylenedioxymethamphetamine, known commonly as Ecstasy) that meet Current Good Manufacturing Practices (“cGMP”) under the SAP for patient needs. The license allows Mydecine to respond to medical practitioner requests for the psychedelic substances for psychotherapy now that Health Canada permits the drugs to be prescribed for treatment-resistant patients (https://ibn.fm/KrWnK). Mydecine established its Special Access Support and Supply Program (“SASSP”) in January to provide the psychotherapy substances along with packaged investigative brochures, therapy manuals, protocol training and advisory services. Post-therapy support for patients is also administered by Mydecine’s wholly-owned subsidiary Mindleap Health under the package (https://ibn.fm/Lk6Q4). An LOI announced last month makes Canadian mental health clinic operator The Newly Institute Inc. Mydecine’s first partner under the SASSP (https://ibn.fm/8PAVW). “While we will continue to advance the research of psychedelic-assisted psychotherapy through our clinical trials and drug development process, we understand there are patients in need of treatments today,” Mydecine Chief Medical Officer Dr. Rakesh Jetly stated. “Through our dealer’s license, we can offer psilocybin and MDMA to practitioners and clinics in Canada who want to offer these treatment options for patients in need.” Mydecine also recently announced that pharmaceutical scientist and global health social entrepreneur Dr. Victoria Hale has joined the company’s Board of Directors. Hale is the board chairwoman of non-profit psychedelic research and mentoring organization Multidisciplinary Association for Psychedelic Studies (“MAPS”), which help scientists design, fund and obtain regulatory approval of studies measuring the safety and effectiveness of psychedelics for therapeutic use, according to the announcement (https://ibn.fm/MoOFV). “With Victoria’s extensive experience and her commitment to bringing life-changing treatments to those who need them, our board members unanimously agreed that she will be an added asset to the company,” Mydecine CEO Josh Bartch stated. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Delic seeks to bring mental health treatment closer to the people through an aggressive expansion plan
• In a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made available
• Studies such as these are helping Delic drive the conversation on psychedelics forward
• The company seeks to take this conversation further with its participation at this year’s Emerald Conference

Over 51.5 million people have experienced a mental health condition in the United States alone, with the figures rising owing to the pandemic. In addition, spending on mental health treatment has grown by 52% since 2009, currently standing at $225 billion. The growth in these figures has increased the demand for alternatives to current therapies, which have been associated with more side effects and less efficacy (https://ibn.fm/xdzmN). Delic Holdings (CSE: DELC) (OTCQB: DELCF) recognizes the opportunity within this market and acknowledges the underlying issues affecting people dealing with mental health conditions, specifically in the United States. As a leader in new medicines and treatments for the modern world, the company is pushing for psychedelic-based treatment adoptions and access to an even wider pool of individuals who could benefit significantly from these treatments. An issue that Delic acknowledges is the lack of access to mental health treatments in general. Most notably, it is estimated that over 112 million Americans live in areas where they cannot access mental health providers, with most establishments located in urban areas. To remedy the issue, Delic has embarked on an aggressive expansion plan that aims to increase the number of its wellness clinics. In 2021, the company completed the acquisition of Ketamine Wellness Centers (“KWC”), a corporation that operates ketamine infusion clinics across nine states. The purchase increased the number of operational wellness clinics under Delic to 12, making the company the largest owner and operator of the most profitable chain of mental health clinics in the United States. These clinics are located in secondary cities instead of urban areas. The objective is to improve accessibility and reach, helping as many people with mental health issues as possible. Over the next 18 months, the company seeks to open 14 additional clinics to improve its reach further and help even more people. Delic is confident in the potential of psychedelics in treating mental health conditions, the reason it is willing to push the conversation forward regarding the adoption of psychedelics as a treatment option. Opening clinics and bringing its products closer to consumers is one way the company is trying to achieve this. The other is by capitalizing on scientific studies to back its claims, sparking the conversation and push for change. On behalf of Delic, a recently-concluded study conducted by The Harris Poll sought to identify what people think of psychedelic medicine to treat anxiety, depression, and Post-Traumatic Stress Disorder (“PTSD”). It was established that 65% of Americans who suffer from these conditions believe that psychedelic medicine should be made more available to patients, particularly those with treatment-resistant conditions (https://ibn.fm/0tzzG). The study also showed that 83% of Americans living with mental health conditions are open to pursuing alternative treatments that have proven to be more effective than prescription medications. In addition, 66% would be open to seeking treatment using ketamine, 62% with psilocybin, and 56% with MDMA, if each was proven more effective and with fewer side effects than prescription drugs. The study, which involved 2,037 adults aged 18 years and above, proved to be an excellent basis for Delic to justify its course and push for the ongoing psychedelic renaissance. The company also seeks to move the conversation even further by leveraging platforms that advance scientific communication and collaboration. Delic has big plans for 2022, and it remains optimistic that it will continue leading what has come to be referred to as the psychedelic renaissance. For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• SRAX has published a replay of its recent 2022 Sequire Metals & Mining Conference, including keynotes, and presentations from 70+ premier companies
• Per the $10 million share repurchase plan announced in Q3 2021, SRAX repurchased approximately $800,000 worth of stock during Q4
• The company also made its first dividend payment through the delivery of preferred stock to shareholders

Most companies use technology to build value for themselves. SRAX (NASDAQ: SRAX) has taken it to a different level, using its technology to build corporate value by showcasing the opportunities in other companies. The Los Angeles-based company operates a portfolio of investor related products and services, including the recently completed 2022 Sequire Metals & Mining Conference. The model is paying dividends, literally. With its proprietary SaaS platform Sequire, SRAX solves some of the most critical problems for public companies and investors alike. For companies, Sequire serves as a big data intelligence and communications platform providing actionable insight about shareholder behavior and trends that can be used to engage current and potential investors via multiple marketing channels. SRAX also owns some preeminent small and microcap investor conferences, which complement their litany of tools that help public companies get noticed by the investment community. For investors, SRAX provides a one-stop shop to declutter an often-confusing digital world and succinctly deliver transparency and due diligence materials that not only help with investment decisions, but also lead to compelling growth opportunities. During SRAX’s 2022 Sequire Metals & Mining Conference, a preeminent virtual investor event held on January 27, investors were treated to keynotes and panel discussions with industry experts and presentations from more than 70 premier metals and mining stock market companies. SRAX has published a replay of the conference, including the talks and individual presentations from all the presenters, available on the event website at https://mining21.mysequire.com/. Company and investor adoption of SRAX as the go-to data provider has bolstered the company’s financial performance over the last year. Earlier this month, management updated shareholders on the company’s $10 million stock repurchase program that was announced in the third quarter of 2021. During the fourth quarter of 2021, the company bought back approximately 155,000 shares of its common stock at an average price of $5.21 per share for a total of approximately $800,000. SRAX also made the first payment for the previously issued dividend. The dividend for the holders of SRAX common stock was paid in the form of preferred shares, which hold shares from SRAX clients that are periodically sold with proceeds to be paid within 30 days following the end of each quarter. The company announced that it sold approximately $380K of this type of shares during the last quarter, which entitled each holder to a cash payment of $0.01 per share due by January 30th, 2022. “We continue to optimize our cap table and return value to our shareholders,” said Christopher Miglino, Founder and CEO of SRAX, in a press release on the developments. “This quarter we re-filed our already existing shelf. This allowed us to eliminate our At the Market filing (“ATM”) and the costs associated with it. We will continue to look for opportunities to reward our shareholders,” he concluded. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• LQwD currently has three public nodes on the Lightning Network – US-West, Singapore, and Frankfurt
• LQwD’s first launched node, US-West has already experienced positive growth
• The company plans to release more international nodes in the future, facilitating its goal of being a prominent payment processor worldwide

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a fintech company focused on creating enterprise-grade infrastructure to drive bitcoin adoption and the development of payment platform-as-a-service (“PaaS”) for the Bitcoin Lightning Network, has announced that it has deployed additional routing nodes in Germany and Singapore. The establishment of these nodes into these international financial hubs translates to providing a gateway to processing payments in the European and Asian markets – faster and with fewer fees (https://ibn.fm/ynAAa). These nodes represent the first of many international nodes that LQwD plans to deploy, secured by company-owned Bitcoin. Watch LQwD CEO & CTO Explain Lightning Network Node Strategy The Lightning Network is a layer-two technology that solves the problem of mass scaling Bitcoin for microtransactions across the globe. The network enables millions of transactions per second, reducing the fees and time required to process them. The Lightning Network has experienced newsworthy growth recently, including (https://ibn.fm/D49Ww):

• Bitcoin capacity increased from 1,060 BTC to 3,444 BTC, representing a growth of over 220% from January 2021 to the present,
• Payment channels are up over 126% since January 31, 2021, growing from 38,000 to presently 87,211 channels, and
• Since April 2021, node growth on the network has increased more than 227%, from 10,394 to 34,453 nodes presently established.

LQwD has three public nodes currently available on the Lightning Network – US-West, Singapore, and Frankfurt. The company launched its first node, US-West, in November 2021 and has experienced positive week-over-week growth, which is expected to occur with the international nodes, as well. LQwD-US-West: Over the last 30 days, US-West has seen a growth of 259.62% (3.594250 BTC/USD$160,342.53), 95.65% increase in channels (44), and an average channel capacity of 0.055 BTC (US$2,467.80).

• Capacity – 4.97865144 BTC
• Value – USD$221,873.15
• Channels – 90
• Connected Nodes – 88

By deploying these and other international nodes, LQwD is positioning itself to participate in the global adoption of the Lightning Network, which is gaining momentum. The company believes that nodes in Germany and Singapore will show capability and proof of concept, which paves the way for LQwD to become a prominent liquidity and payment processor globally. The Bitcoin payment ecosystem market is expanding steadily, being expected to reach a value of US$880 million by 2026, growing at a CAGR of 20.13% (https://ibn.fm/JbqPc). The market comprises miners, traders, merchants, hoarders, and consumers. Still, it is directly affected by the market exchange rate, non-compliance, and the flexibility to utilize Bitcoin for payment in commercial and e-commerce settings. The legal adoption of Bitcoin as a tender is also expected to drive significant growth for the market. Countries like El Salvador have already begun transitioning to a crypto-economy. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

Biotech experts, top LSD researchers, science specialists, influencers, and medical professionals are invited to attend the virtual LSD Conference being held on February 17, 2022. The agenda of the conference will include discussions, keynotes, and insights from world-class speakers focused on the research regarding therapeutic benefits and potential of LSD. The conference is organized by Microdose, a premier organization engaged in creating, offering and distributing the most compelling content on the finance, industry news, science, and the latest breakthroughs and events of the psychedelic industry. This is the biggest platform offering exposure to professionals, companies, and individuals about the events of the psychedelic industry. The title sponsor of the virtual event is MindBio Therapeutics, a clinical-stage drug development company engaged in the research of microdosing and the medicinal benefits of psychedelic medicines in treating debilitating mental illnesses. This 2-day virtual event will explore the scope and potential of LSD along with discussing the latest innovations in drug development, clinical safety and care, the laws and regulations, science and research, culture and creativity, as well as business trends. This LSD event offers a phenomenal platform and a huge breadth of audience. The attendees can interact with industry influencers and organizations who will discuss the future potential of LSD in different sectors. They will learn the varied uses of LSD and its potential non-psychedelic uses, its role in healing debilitating mental conditions, drug development and safety, clinical applications, and its creative effects, to name a few. This conference is a great networking medium where businesses and professionals can connect to build relationships and explore the latest innovations in psychedelic science. The major points of discussion at the conference include:

• Therapeutic Use of LSD in Psychiatry
• Posology and Tolerance to Regression
• Safety and Efficacy of Lysergic Acid Diethylamide Assisted Psychotherapy
• LSD Microdosing
• Effect of Lysergic Acid Diethylamide (“LSD”) on Learning
• The Effects of LSD on Creativity

Attendees buying tickets to the event can attend the sessions, live presentations, group discussions as well as avail networking opportunities in one-to-one meetings with dedicated companies. Also, they will have lifetime access to the live recordings and will be added to the My content section of the website of every ticketholder’s account within 5 business days following the event. For more information visit https://ibn.fm/xE23e.

• Recent research efforts have targeted the potential of cannabis compounds to combat COVID-19 infection as the worldwide pandemic presses forward into its third year
• Perhaps most notable among the early-stage research efforts is a study by Oregon State University that found high doses of two specific cannabinoids bound to spike proteins such as COVID’S SARS-CoV-2 and inhibited their potential for infection
• Cannabis cultivator and brand builder Flora Growth Corp. has filed a provisional patent application for a cannabinoid-based formula that it is simultaneously seeking approval from Colombia’s food and drug regulatory authority for a study and potential clinical trial in fighting COVID
• Flora Growth hopes to fast-track the product for potential commercialization as a therapeutic for combating the virus
• Flora also recently named James Choe, the founder of its cannabis technology acquisition Vessel, as Flora’s new chief strategy officer to help establish the company’s direction in the coming years

A number of recent studies have signaled the possibility that cannabis derivative products may be beneficial in preventing COVID infections or combatting them once they have caused sickness. The baseline studies have generated enough excitement that cannabis cultivator and worldwide cannabidiol (“CBD”) brand builder Flora Growth (NASDAQ: FLGC) is asking Colombia’s food and drug regulatory agency to approve the company’s plans for more rigorous research into a patent-pending, cannabinoid-based product to fight viruses such as COVID’s SARS-CoV-2. “At Flora Growth we believe in following the research, and there have been several promising studies published in just the last few months on the application of cannabinoids in certain treatments. We are excited for our Flora Pharma researchers to build upon this progress and generate new data for how cannabis could help consumers around the world, leveraging this natural, botanical alternative,” Flora Growth President and CEO Luis Merchan stated in the company’s Feb. 2 announcement (https://ibn.fm/bsSPn). Flora Growth is asking Colombia’s regulatory Instituto Nacional de Vigilancia de Medicamentos y Alimentos (“INVIMA”) to provide guidelines for researching cannabis products’ effects on the SARS-CoV-2 virus under emergency use authorization protocols that let Flora pursue the fastest path to market for a product that would serve as an immune system-enhancing preventative therapeutic. The potential for cannabis compounds found in non-psychoactive hemp to act in a COVID prevention capacity was announced by Oregon State University researchers in late January after they found that high doses of cannabigerolic acid, or CBGA, and cannabidiolic acid, or CBDA, prevented infection of human epithelial cells by “a pseudovirus expressing the SARS-CoV-2 spike protein” and prevented entry of live SARS-CoV-2 into cells (https://ibn.fm/OMS0t). The study’s authors note that the compounds are orally bioavailable and have a long history of safe human use. The compounds worked by binding to spike proteins found on the virus and preventing it from following a process it uses to infect people, although the study didn’t go so far as to give the supplements to people and compare their effectiveness in patients to those who wouldn’t receive the substances (https://ibn.fm/WoG7d). A Reuters report on the development noted similar research that found small doses of highly purified CBD did not keep the coronavirus from infecting cells in test tubes, but rather acted soon after the virus entered the cells, blocking it from making copies of itself. The researchers also found small doses of cannabis compounds tetrahydrocannabinol (“THC”), cannabidivarin (“CBDV”), cannabichromene (“CBC”) and cannabigerol (“CBG”) — as well as CBDA — did not keep the virus out of cells or prevent it from replicating, and that THC actually prevented the CBD from working. The high doses of CBDA and CBGA used in the OSU study “were non-toxic to cells. (But) it is not clear yet that similarly high doses would be safe for humans,” study author Richard van Breemen told Reuters (https://ibn.fm/jadgD). Flora’s research division, Flora Pharma, has filed a provisional patent application on a cannabinoid-based formula and with INVIMA’s backing would take the product through clinical trials that would exceed the early-stage research done by the other entities, the company states. Flora Pharma is based at the company’s Cosechemos cultivation facility in central Colombia, and approval would mark the first emergency use authorization granted by INVIMA for cannabinoid therapies against COVID. “I have worked on various aspects of SARS-CoV-2 research for the last two years, with a focus on cannabinoid therapeutics more broadly,” Flora Pharma managing scientist Dr. Annabelle Manalo-Morgan stated. “I believe the Flora team is best positioned to formulate, test and ultimately bring to the market this kind of novel product offering.” As Flora Growth establishes its direction for the coming years, the company named James Choe, the founder and CEO of premium cannabis consumption facilitator Vessel, as Flora’s chief strategy officer (https://ibn.fm/ZW0Yr). Flora acquired Vessel’s sustainable technology and accessories late last year (https://ibn.fm/yfx8A). For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• NMRD CEO Dr. Faz Chowdhury presented at H.C. Wainwright BioConnect Conference held January 10-13, 2022
• Presentation revealed growing need for CGM devices, diabetes market estimated at $150 billion
• NMRD’s sugarBEAT(R) devices measure glucose at the skin surface, non-invasive, easy to use
• NMRD recently commenced product shipments in lieu of an order for 5,000 CGM devices and 200,000 sensors to UK licensing partner MySugarWatch Limited
• NMRD recently announced launch of Miboko metabolic health program targeted at global employers and insurers

Dr. Faz Chowdhury, CEO of Nemaura Medical (NASDAQ: NMRD), recently presented at the H.C. Wainwright BioConnect Conference on January 10-13, 2022, where he discussed the growing diabetes problem and how Continuous Glucose Monitoring (“CGM”) devices can help patients manage symptoms and reverse the disease (https://ibn.fm/HPL7B). Nemaura is a medical technology company that develops affordable, non-invasive wearable diagnostic devices and digital tools for chronic disease management. The company is currently commercializing its sugarBEAT(R) and proBEAT(TM) non-invasive and flexible wearable glucose monitoring devices that provide insights to help diabetic and pre-diabetic people better prevent, manage, and reverse the onset of the disease. During his presentation, Dr. Chowdhury revealed that there are over 463 million diabetes patients worldwide amid a growing market estimated at $150 billion. NMRD’s vision is to lead the industry in the prevention, management, and reversal of diabetes with low-cost, flexible, and user-friendly devices and health coaching programs. Unlike traditional glucose monitoring methods, NMRD’s sugarBEAT(R) devices are non-invasive and use a well-established glucose oxidase enzyme methodology to convert glucose at the skin’s surface to an electric current signal. Low energy Bluetooth connectivity then sends this information to the complimentary phone app every five minutes, where it’s converted to a glucose value that is presented to the user. With these insights, users can make critical lifestyle decisions to help prevent or manage symptoms. The company is currently commercializing sugarBEAT(R) and in December 2021 commenced shipments in lieu of an order for 5,000 CGM devices and 200,000 sensors to MySugarWatch Limited, its UK licensing partner. MySugarWatch Limited plans to market the devices to nearly 5 million diabetics and 13.6 million at-risk people in the UK with a subscription model that includes a coaching and management service (https://ibn.fm/tOTMu). In addition, NMRD launched Beta trials of Miboko, a new metabolic health program targeted at global employers and insurers (https://ibn.fm/Yd5xE) as well as the direct to consumer market. In 2011, NMRD initially created a single platform technology that measures blood markers at the skin’s surface and has since adapted the technology to develop non-invasive glucose-monitoring wearable devices. With a unique position at the intersection of both diabetes and weight loss markets, Nemaura is positioned favorably with its proprietary technology in the rapidly growing medical wearable device industry. For more information, visit the company’s website at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technology
• Kernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experience
• CYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/f0HXk). The approval, granted by the Institution Review Board (“IRB”), gives a green light to a Cybin-sponsored study designed around Kernel’s quantitative neuroimaging technology, Kernel Flow. “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and collect quantitative data as opposed to subjective patient reporting,” said Cybin CEO Doug Drysdale. “We believe the results of this study will lead to future studies that will test the effectiveness of psychedelic treatments and will further support our mission to develop psychedelics into therapeutics.” Early last year, Cybin partnered with Kernel to leverage Kernel’s proprietary Kernel Flow device for psychedelic-based studies and clinical trials (https://ibn.fm/rRZbn). The first-of-its-kind device uses quantitative neuroimaging technology to measure brain activity in real time using a wearable helmet during psychedelic treatments. In June 2021, Cybin announced it would be sponsoring a feasibility study of the Kernel Flow technology and ketamine. As part of that sponsorship, Cybin has the rights to any innovations that are discovered or developed through its independent analysis of the study findings. The study received U.S. Food and Drug Administration Investigational New Drug (“IND”) authorization in October 2021, and enrollment is expected to begin in the coming weeks. “We still have much to learn about what is occurring in the brain during a psychedelic experience,” said Drysdale. “This first-of-its-kind, Cybin-sponsored study using the Kernel Flow device aims to expand our physiological understanding of psychedelic pharmacotherapy. We are excited to be part of this pioneering journey with our partners at Kernel.” Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. In contrast with electroencephalography (“EEG”) electrodes that usually require gel on the head or functional magnetic resonance imaging (“fMRI”) studies that require lying in a scanner, the Flow device is a wearable helmet with potential for wide use in neuroscientific or physiological studies of brain activity during psychedelic use. To date, direct neuroimaging research of psychedelic effects is rare and has never been attempted with a wearable device. Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Ammonia is less expensive to transport long-distance via seaborne vessels than liquid hydrogen
• Ammonia has a lower boil-off rate and higher volumetric energy density than liquid hydrogen; additionally, an ammonia carrier requires less capital investment than a liquid hydrogen transportation vessel
• FuelPositive holds that green ammonia is a perfect substitute for transporting and storing hydrogen because of existing infrastructure
• The company recently provided a corporate update in which it detailed the progress of the building of the first demonstration systems for its green ammonia production technology

While the hydrogen economy envisions a decarbonized future where green hydrogen is used to power transportation vessels, a Recharge special report observes that physics and cost back ammonia as a more economic option for long-distance seaborne transportation than liquid hydrogen (“LH2”) (https://nnw.fm/7nHPX). (https://ibn.fm/UJnL4). These findings dovetail perfectly with part of the vision Canadian growth-stage technology company FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) has for its modular, scalable, and portable green ammonia production technology. The system, designed to produce green ammonia from water, air, and renewable electricity, is touted as a solution to the hydrogen transportation conundrum. According to FuelPositive, green ammonia, which is hydrogen dense and is much easier to store and transport using existing infrastructure, is the perfect vector for hydrogen. As a liquid, hydrogen needs cryogenic temperatures of -253°C, while as a gas, it has to be kept at extremely high pressure. At the same time, it is explosive when it escapes and combines with air (https://nnw.fm/tcwkB). (https://ibn.fm/5oJkB). These characteristics mean that long-distance hydrogen transportation may not be entirely practical. These sentiments are shared by Leigh Collins, the Recharge special report’s author, who notes that because the volumetric density of liquid ammonia is 59% higher than LH2, “it would theoretically take more than three shipments of LH2 to transport the same amount of energy as two shipments of liquid ammonia,” assuming same-sized vessels. Further, Recharge established that a 160,000m³ cargo (a standard LNG vessel size) of liquid hydrogen would cost about $200 per MWh to produce, in terms of the energy it contains, compared to just under $88/MWh of liquid ammonia. In addition, LH2 transportation would result in a $270.5 million annual loss from boil-off compared to $4.1 million when liquid ammonia is transported. With LH2 requiring colder cryogenic temperatures of -253°C to remain as a liquid, compared to liquid ammonia’s -33°C, the Recharge article notes that the latter’s lower annual losses “could be due to the fact that existing ammonia carriers are often fully refrigerated to keep the ammonia in its liquid state – something that isn’t possible with far colder LH2.” The article further points out that the capital cost of a vessel carrying 160,000 cubic meters of LH2 would be higher than one holding the same volume of liquid ammonia. “Taking all these elements into account, it is clear that ammonia would be far less expensive to transport by sea than liquid hydrogen,” Collins writes. FuelPositive’s system is even more advantageous as it uses less energy than conventional (“grey”) ammonia production, which involves the energy-intensive and extremely dirty Haber-Bosch process. In addition, it is 100% carbon-free. Meanwhile, FuelPositive recently announced it had filed its annual audited financial statements and provided a corporate update (https://nnw.fm/4UHU7). (https://ibn.fm/aDEdA). In its update, contained in a NetworkNewsAudio presentation, the company noted that the building of the first demonstration systems for the green ammonia production technology was progressing according to plan and that it expects to commence validating the system in the first half of the year. The validation is anticipated to prove the rate and purity of the produced green ammonia. The company has also selected a farm in Manitoba, Canada, to serve as the first demonstration pilot project. FuelPositive will deploy the first prototype in this location later this summer. Finally, FuelPositive announced advisory appointments as well as the fact that it has identified the Kitchener-Waterloo area as the location for its head office. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://nnw.fm/NHHHF https://ibn.fm/NHHHF

• Health and wellness drug bio-effectiveness innovator Lexaria Bioscience is advancing human testing of its patented DehydraTECH(TM) technology for the potential treatment of high blood pressure and heart disease
• Lexaria also recently announced that DehydraTECH boosted the speed and effectiveness of sildenafil in laboratory rats for the potential treatment of erectile dysfunction (“ED”)
• The company’s statement notes that DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation”
• ED affects some 30 million men in the United States and is expected to affect about 322 million men worldwide by 2025

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has made a case for increasing the rapidity and effectiveness of medication absorption through Lexaria’s patented DehydraTECH(TM) technology. Recent clinical studies have shown the potential for improved bio-effectiveness of nicotine and cannabidiol (“CBD”) when processed with DehydraTECH for the potential treatment of conditions such as high blood pressure and arterial stiffness, for example. In a Feb. 2 news release, the company announced it has also observed successes when administering DehydraTECH-processed sildenafil to lab rats to study the potential of Lexaria technology in improving the treatment of erectile dysfunction. Viagra, the most widely known sildenafil product in the world, “is moderately bioavailable orally at roughly 40%, but many people find it slow to act,” Lexaria’s news release states (https://ibn.fm/M6FGU). The company’s PDE5-A21-1 animal study found DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation.” The study suggests sildenafil may take effect much more quickly when processed with DehydraTECH than without it. Seven minutes after the animals received their doses, the DehydraTECH-sildenafil formulation reached an average blood level higher than the generic sildenafil control formulation reached at any point during the study, the company states. The landmark Massachusetts Male Aging Study completed in 1994 reported that 52 percent of men experience some form of erectile dysfunction (“ED”), while other more recent studies have found that about 30 million men in the United States may be affected, with about 322 million men worldwide expected to be affected by 2025 (https://ibn.fm/wotN5). Lexaria’s study could be a boon for Viagra or its generic pharmaceutical competitors in responding to the market for ED solutions that are faster and more effective than current options. The company noted that despite a clear trend toward faster and higher overall delivery of sildenafil into the bloodstream, the improvements in delivery rate did not achieve statistical significance so further investigation with a larger number of animals may be needed. In the meantime, human clinical studies evaluating DehydraTECH’s potential for treating hypertension in combination with CBD are ongoing. In December, the U.S Food and Drug Administration (“FDA”)-registered Independent Review Board (“IRB”) approved the protocols for HYPER-H21-4, which is tentatively expected to begin dosing by April to measure 24-hour ambulatory blood pressure (the primary outcome), blood biomarkers (including lipids such as cholesterol), sleep disorders and perceived stress (https://ibn.fm/PI9QR). These markers will provide information on DehydraTECH-CBD’s impact on chronic heart disease, following on the positive results of the blood pressure studies. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX